Navigation Links
Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
Date:6/15/2009

ith GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
2. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
3. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
4. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
5. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
6. Amira Pharmaceuticals Appoints First Vice President of Development
7. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
8. Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study
9. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
10. Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results
11. Isis Pharmaceuticals to Present at Jefferies 3rd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... presence of chronic inflammation in benign prostate tissue ... and this association was found even in those ... a study published in Cancer Epidemiology, Biomarkers ... Association for Cancer Research. , An analysis of ... the placebo arm of the Prostate Cancer Prevention ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... health committee is all set to tighten the screws ... days of public hearing starting on Jan 23, is ... will make submissions before the committee. ,Under ... the sponsorship of sports and other popular events by ...
... way that primary care is organized, delivered, financed, and ... were released today by the American College of Physicians ... the Nation's Health Care. ,The U.S. health ... medicine, the ACP reported in its January 2006 State ...
... viral culture system, which makes way for a better ... replication of virus// (isolated from patient) in non-transformed hepatocytes. ... in transformed cell lines. ,The study report ... transfected and serum-infected cultured human fetal hepatocytes,’ appears in ...
... been accomplished by people who have kept on trying when there ... ,A groundbreaking venture has been ... cancer-treatment, are mass-produced in the egg white of a certain breed ... is one of the leading causes of death in the world. ...
... known as microchimerism has been known for some years, that ... pregnancy, and that these may live on for many// years, ... still unclear as to whether the presence of such cells ... team has looked for maternal cells in children with type ...
... findings that point to yet another benefit of statins; improving ... prescribed for heart patients. They work by lowering the levels ... in arteries. ,The drugs have also been shown ... of heart disease from having a heart attack or stroke. ...
Cached Medicine News:Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 2Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 3Health News:A Breakthrough in the Study of Hepatitis C 2Health News:'Hen Factories' To Synthesize Cancer Drugs 2Health News:Stem Cells Passed From Mother to Child Live On and Make Insulin 2Health News:Statins Aid Survival in Lung Patients, Say Experts 2
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , , , ... announced the start of a phase II human clinical trial of ... people with diabetes mellitus. The randomized, controlled 12-week trial in patients ... Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, ...
... Potential to Treat a Broad Spectrum of Migraine,***UPDATED SATELLITE ... common, debilitating neurological disorder that affects,approximately 30 million people ... Limitations of oral triptans, the class of,prescription drugs widely ... between 45 and 90 minutes, substantial variability in,patient response ...
Cached Medicine Technology:Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes 2MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS 2
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
... Medtronic InSync ICD cardiac resynchronization and ICD ... seconds (BOL). The unit's RV only sensing ... RV and LV depolarizations, eliminating this cause ... RV to LV separation for optimized hemodynamics. ...
... The Guidant Contak Renewal 3 ... ventricular tachyarrhythmia therapy and cardiac ... right ventricular (RV) and left ... Designed to reduce irregular ventricular ...
... The RapidLoc Meniscal Repair ... system that offers several advantages ... suture repair techniques and current ... is quick, simple, reproducible, reliable, ...
Medicine Products: